Compare Essex Property Trust, Inc. (ESS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Essex Property Trust, Inc. trades at $281.67 (market cap $18.15B), while IDEXX Laboratories, Inc. trades at $571.23 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.5× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ESS | IDXX | |
|---|---|---|
Market Cap | $18.15B | $46.22B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $766.68 |
52-Week Low | $239.61 | $526.44 |
Enterprise Value | $24.75B | $47.12B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $282.11, down 0.39% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.97, missing expectations, but raised full-year guidance after strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is trending lower in 2026. Recent news includes ESS being named a top GreenTech company and signing a 500 MWh energy storage agreement with Juniper Energy.
The outlook is mixed: raised guidance and institutional buying support upside, but technical weakness and earnings miss pose near-term risks. Valuation ratios like P/E of 19.9 and P/S of 9.05 are reasonable for a REIT, yet debt levels and regional market volatility require caution. Analyst consensus is a Moderate Buy with a $305.86 price target, suggesting 8.4% potential upside from current levels.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
